相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
Jan P. Boettcher et al.
CELL (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer
Raghvendra M. Srivastava et al.
CLINICAL CANCER RESEARCH (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma
Anna Laurell et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy (vol 28, pg 44, 2017)
A. R. Sanchez-Paulete et al.
ANNALS OF ONCOLOGY (2017)
Constitutive resistance to viral infection in human CD141+ dendritic cells
Aymeric Silvin et al.
SCIENCE IMMUNOLOGY (2017)
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Abigail E. Overacre-Delgoffe et al.
CELL (2017)
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy
Stefani Spranger et al.
CANCER CELL (2017)
Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma
Edward W. Roberts et al.
CANCER CELL (2016)
The Basis of Oncoimmunology
A. Karolina Palucka et al.
CELL (2016)
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
Chan-Young Ock et al.
CLINICAL CANCER RESEARCH (2016)
Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
Helene Salmon et al.
IMMUNITY (2016)
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma
Stefani Spranger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
Soumaya Karaki et al.
VACCINES (2016)
Therapeutic cancer vaccines
Cornelis J. M. Melief et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf
Linda Hammerich et al.
MOLECULAR ONCOLOGY (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment
Thomas F. Gajewski
SEMINARS IN ONCOLOGY (2015)
Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication
Oana Draghiciu et al.
ONCOIMMUNOLOGY (2015)
Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells
Florence Deauvieau et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2014)
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
J. J. Ko et al.
BRITISH JOURNAL OF CANCER (2014)
Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells
Brian Ruffell et al.
CANCER CELL (2014)
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity
Miranda L. Broz et al.
CANCER CELL (2014)
Tumor-Associated Macrophages: From Mechanisms to Therapy
Roy Noy et al.
IMMUNITY (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Personal neoantigen cancer vaccines The momentum builds
Edward F. Fritsch et al.
ONCOIMMUNOLOGY (2014)
Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
Raghvendra M. Srivastava et al.
CLINICAL CANCER RESEARCH (2013)
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
Nienke van Rooij et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
IL-1R signaling in dendritic cells replaces pattern-recognition receptors in promoting CD8+ T cell responses to influenza A virus
Iris K. Pang et al.
NATURE IMMUNOLOGY (2013)
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Paul F. Robbins et al.
NATURE MEDICINE (2013)
Influenza A Virus Infection of Human Primary Dendritic Cells Impairs Their Ability to Cross-Present Antigen to CD8 T Cells
Anna Smed-Soerensen et al.
PLOS PATHOGENS (2012)
Cross-presentation by dendritic cells
Olivier P. Joffre et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Direct activation of antigen-presenting cells is required for CD8+ T-cell priming and tumor vaccination
Wolfgang Kratky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
CD8+T Cell Priming by Dendritic Cell Vaccines Requires Antigen Transfer to Endogenous Antigen Presenting Cells
Alice W. Yewdall et al.
PLOS ONE (2010)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko et al.
CLINICAL CANCER RESEARCH (2009)
Interferon-γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages
Dorothee Duluc et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Maturation Pathways of Dendritic Cells Determine TAP1 and TAP2 Levels and Cross-presenting Function
Andres Lopez-Abaitero et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine
Karin Gustafsson et al.
CANCER RESEARCH (2008)
Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation
Ravikumar Muthuswamy et al.
CANCER RESEARCH (2008)
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
E Suzuki et al.
CLINICAL CANCER RESEARCH (2005)
Direct allorecognition promotes activation of bystander dendritic cells and licenses them for Th1 priming:: A functional link between direct and indirect allosensitization
AC Wallgren et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2005)
Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells
G Napolitani et al.
NATURE IMMUNOLOGY (2005)
Herpes simplex virus infection of human dendritic cells induces apoptosis and allows cross-presentation via uninfected dendritic cells
L Bosnjak et al.
JOURNAL OF IMMUNOLOGY (2005)
Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells
JF Fonteneau et al.
BLOOD (2003)
Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction
PL Vieira et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
